Advanced Search
Contact | Corporate | Help

A Study Evaluating the Efficacy and Safety of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

Sponsors:
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Basal Cell Carcinoma
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: GDC-0449
Enrollment:
100

Additional information about NCT00833417.


SourceSolution © 2008-2012